Small pharma firms may face closure as regulator tightens quality checks
Thousands of micro, small and medium pharmaceutical companies may face closure, as the drug regulator has ordered inspections of facilities to verify their compliance with Schedule M good manufacturing practices, potentially causing drug shortages, industry insiders said. As many as 5,000 drug manufacturing plants, struggling with high costs required to upgrade, may shut doors, according…